0001209191-20-009652.txt : 20200214
0001209191-20-009652.hdr.sgml : 20200214
20200214162259
ACCESSION NUMBER: 0001209191-20-009652
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200213
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cui Jingrong Jean
CENTRAL INDEX KEY: 0001772259
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38871
FILM NUMBER: 20620366
MAIL ADDRESS:
STREET 1: C/O TURNING POINT THERAPEUTICS, INC.
STREET 2: 10628 SCIENCE CENTER DR., STE. 225
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc.
CENTRAL INDEX KEY: 0001595893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463826166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-926-5251
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, Inc.
DATE OF NAME CHANGE: 20181018
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, INC
DATE OF NAME CHANGE: 20140106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-13
0
0001595893
Turning Point Therapeutics, Inc.
TPTX
0001772259
Cui Jingrong Jean
C/O TURNING POINT THERAPEUTICS, INC.
10628 SCIENCE CENTER DRIVE, STE. 200
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
1301298
D
Common Stock
2020-02-13
4
S
0
200
59.83
D
792519
I
By spouse
Common Stock
2020-02-13
4
S
0
2400
60.70
D
790119
I
By spouse
Common Stock
2020-02-13
4
S
0
8800
62.18
D
781319
I
By spouse
Common Stock
2020-02-13
4
S
0
100
63.07
D
781219
I
By spouse
Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
The weighted average sale price for the transaction reported was $59.83, and the range of prices were between $59.46 and $60.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $60.70, and the range of prices were between $60.47 and $61.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
The weighted average sale price for the transaction reported was $62.18, and the range of prices were between $61.79 and $62.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Annette North, Attorney-in-Fact
2020-02-14